1.
Arifaj B, Habad M, Hamzat M, Webb M, Oweis EC. Preoperative optimisation before revision total hip arthroplasty: a systematic review of modifiable risk factors and optimisation strategies. Orthopedic Reviews. 2026;18. doi:10.52965/001c.173780
Download all (1)
  • Figure 1. PRISMA 2020 flow diagram of study selection.

Abstract

Introduction

Revision total hip arthroplasty (rTHA) is associated with perioperative morbidity and healthcare utilisation. Preoperative optimisation may improve outcomes, but revision-specific evidence remains poorly defined.

Objective

To evaluate preoperative factors and optimisation strategies associated with rTHA outcomes and identify areas where evidence for active intervention remains lacking.

Methods

PubMed, MEDLINE and Embase were searched from inception to September 2026 for primary studies evaluating preoperative optimisation, modifiable risk factors or related interventions in adults undergoing rTHA. Risk of bias was assessed using the Newcastle-Ottawa Scale and PROBAST principles. Owing to clinical and methodological heterogeneity, findings were synthesised narratively.

Results

The search identified 226 records; 103 remained after 123 duplicates were removed, and 15 studies were included. No randomised controlled trials were identified. Anaemia was the most consistently investigated potentially modifiable factor and was associated with transfusion, complications, prolonged length of stay and readmission. Hypoalbuminaemia, chronic opioid exposure, depression, obesity, impaired functional status, renal dysfunction, liver disease and cardiopulmonary comorbidity also identified higher-risk patients. An opioid-free interval was associated with attenuation of excess risk in one observational study. Fast-track pathways reduced length of stay, although readmission remained high. No eligible study directly investigated structured preoperative physiotherapy or exercise-based prehabilitation specifically before rTHA.

Conclusion

Multiple potentially modifiable preoperative factors are associated with adverse outcomes following rTHA, with anaemia demonstrating the most consistent revision-specific evidence. However, current literature is predominantly retrospective and prognostic, and evidence that active correction of identified risks improves outcomes remains limited. Prospective interventional studies, particularly of multimodal optimisation and exercise-based prehabilitation, are required.

Introduction

Total hip arthroplasty (THA) is an established treatment for end-stage hip disease, providing substantial improvements in pain, mobility and quality of life. However, as the number of primary procedures performed increases and patients live longer with their implants, the requirement for revision total hip arthroplasty (rTHA) is also expected to rise. Contemporary modelling of United States Medicare data projected the annual number of rTHAs to increase by approximately 42% between 2020 and 2040 and to more than double by 2060.1 Earlier National Inpatient Sample modelling similarly projected a 43-70% increase in rTHA between 2014 and 2030, with particularly substantial growth anticipated among younger patients and revisions performed for infection.2 Although these projections arise from United States datasets and may not be directly generalisable to other healthcare systems, they illustrate the increasing clinical and resource burden posed by revision hip arthroplasty.

The indications for rTHA are heterogeneous and include instability, periprosthetic joint infection (PJI), aseptic loosening, polyethylene wear, osteolysis and periprosthetic fracture. In a recent analysis of more than 100,000 rTHA procedures performed between 2016 and 2022, dislocation and infection were among the most frequently recorded indications for revision, followed by periprosthetic fracture.3 This heterogeneity is important because the physiological and technical demands of revision surgery vary considerably according to indication. An elective component exchange for aseptic failure differs substantially from complex reconstruction for severe bone loss, revision for PJI or surgery following periprosthetic fracture. Consequently, both the opportunity for preoperative optimisation and the risks associated with delaying surgery are likely to vary between patients.

Although rTHA can provide meaningful improvements in pain, function and quality of life, outcomes are generally less favourable than following primary THA. Postler et al. demonstrated that patients undergoing revision surgery experienced significant improvements in patient-reported outcomes but achieved smaller gains in osteoarthritis, activity and quality-of-life measures than matched patients undergoing primary THA.4 Similarly, Zhang et al. found lower rates of clinically meaningful improvement and lower patient satisfaction following rTHA compared with primary THA.5 These findings emphasise that successful revision surgery depends not only on reconstruction of the implant and management of the underlying mode of failure, but also on the physiological reserve and preoperative condition of the patient.

Revision surgery also carries substantial perioperative consequences. Mortality following rTHA varies according to patient characteristics and the indication for revision; Laughlin et al. reported an overall two-year mortality rate of 19.5 per 1,000 revision procedures, with markedly greater mortality following revision for periprosthetic fracture.6 Revision surgery additionally places a considerable economic burden on healthcare systems. In a United Kingdom tertiary referral centre, Vanhegan et al. found that costs differed substantially according to revision indication, with septic revision and revision for periprosthetic fracture associated with particularly high costs, longer hospitalisation, greater blood loss and increased complications.7 As demand for rTHA rises, strategies capable of reducing preventable complications, length of stay and resource utilisation therefore have increasing clinical and economic importance.

Preoperative optimisation has consequently become an increasing focus within elective arthroplasty. Rather than regarding preoperative assessment solely as confirmation of fitness for anaesthesia, contemporary optimisation strategies aim to identify potentially modifiable factors before surgery and intervene where feasible. In primary total joint arthroplasty, factors including obesity, malnutrition, anaemia, diabetes, smoking and chronic opioid exposure have been associated with poorer outcomes and have been proposed as targets for preoperative intervention.8 However, evidence developed in primary arthroplasty cannot necessarily be extrapolated directly to rTHA. Revision patients frequently have greater comorbidity, chronic pain, reduced mobility, previous surgical exposure and more complex pathology, while septic and mechanically unstable cases may also provide substantially less time for optimisation.

Furthermore, optimisation encompasses more than medical comorbidity alone. Potential strategies include correction of anaemia and nutritional deficiency, modification of lifestyle factors, management of obesity and chronic disease, rationalisation of opioid use, psychological support, physiotherapy and exercise-based prehabilitation. These interventions are intended either to reduce specific perioperative risks or to improve physiological and functional reserve before major surgery. Despite the intuitive rationale for such measures, the extent to which they have been specifically investigated in rTHA remains unclear. In particular, there is a need to distinguish evidence demonstrating that a preoperative characteristic predicts poor outcome from evidence demonstrating that modification of that characteristic actually improves postoperative outcome.

The aim of this systematic review was therefore to evaluate the available evidence regarding preoperative optimisation before rTHA, with particular emphasis on potentially modifiable patient factors and interventions including physiotherapy, exercise and prehabilitation, lifestyle modification, nutritional optimisation, anaemia management, medication exposure, psychological health and optimisation of medical comorbidity. A secondary aim was to identify areas in which adverse prognostic factors have been described but evidence for effective intervention remains lacking, thereby defining priorities for future revision-specific optimisation research.

Methods

Study design and reporting

A systematic review was conducted to evaluate preoperative factors and optimisation strategies associated with outcomes following rTHA. The review was conducted and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidance. The review focused on potentially modifiable preoperative factors, including anaemia, nutritional status, obesity, medication use, psychological comorbidity, lifestyle factors, medical comorbidities, physical function and structured perioperative optimisation pathways. Particular interest was given to interventions or exposures that could potentially be addressed before revision surgery.

Search strategy

A systematic literature search was performed using PubMed, MEDLINE and Embase from inception to September 2026. The search strategy was developed around three principal concepts: hip arthroplasty, revision surgery and preoperative optimisation. Procedure terms included “hip arthroplasty”, “hip replacement”, “THA”, “revision”, “revision arthroplasty”, “revision joint arthroplasty” and “revision total joint arthroplasty”. These were combined with terms including “prehabilitation”, “preoperative rehabilitation”, “preoperative physiotherapy”, “preoperative physical therapy”, “preoperative exercise”, “preoperative optimisation/optimization”, “preoperative care”, “preoperative management”, “preoperative preparation”, “patient optimisation/optimization”, “lifestyle modification”, “risk factor modification” and “modifiable risk factor”. Appropriate Medical Subject Headings and database-specific indexing terms were used where applicable. Boolean operators AND and OR were used to combine concepts, and each strategy was adapted to database syntax. No publication-date restriction was applied. Complete search strategies are presented in Supplementary Appendix 1.

Eligibility criteria

Studies were eligible if they investigated adults aged 18 years or older undergoing rTHA and assessed a preoperative factor, exposure, intervention or optimisation strategy in relation to postoperative outcomes. Studies containing both revision hip and knee populations were eligible where rTHA represented a defined component and the exposure was applicable to revision arthroplasty; hip-specific results were extracted preferentially where available. Potentially modifiable factors included anaemia and haemoglobin status, nutritional status and hypoalbuminaemia, vitamin deficiency, obesity and body mass index, preoperative opioid exposure, psychological comorbidity, renal and hepatic dysfunction, pulmonary and cardiovascular disease, physical function, and structured enhanced-recovery or optimisation pathways. Studies of preoperative physiotherapy, exercise or prehabilitation were also eligible.

Eligible studies were required to report at least one clinically relevant postoperative outcome, including medical or surgical complications, transfusion, PJI, treatment failure, reoperation or re-revision, mortality, length of stay, readmission, emergency department attendance, discharge destination or healthcare utilisation. Randomised controlled trials, prospective and retrospective cohort studies, case-control studies and other comparative primary clinical studies were eligible. Narrative or systematic reviews, editorials, commentaries, letters, case reports, conference or poster abstracts without sufficient full-text data and non-clinical studies were excluded. Studies involving only primary THA were excluded. Only English-language publications were included.

Study selection and data extraction

All records identified through the three databases were combined and duplicates removed before screening. Titles and abstracts were assessed against the predefined eligibility criteria, followed by full-text assessment of potentially eligible articles. Review articles identified during full-text assessment were excluded from the primary evidence synthesis but retained as background sources. The selection process was documented using a PRISMA 2020 flow diagram.

Data were extracted using a standardised framework, including author, year, country or database of origin, study design, study period, sample size, revision procedure, indication for revision, patient characteristics, preoperative exposure or optimisation factor, comparator, follow-up and relevant postoperative outcomes. Where available, adjusted and unadjusted effect estimates were recorded, including odds ratios (ORs), 95% confidence intervals (CIs), P values and area under the receiver operating characteristic curve (AUC). Proposed threshold values were also extracted. For mixed hip and knee populations, hip-specific sample sizes and estimates were extracted where reported; pooled results were not assumed to represent rTHA independently.

Outcomes, risk of bias and synthesis

Studies were grouped according to the principal preoperative factor investigated: haematological optimisation; nutritional and metabolic optimisation; opioid exposure; psychological health; obesity, functional status and general comorbidity; renal, hepatic and cardiopulmonary disease; and multimodal or enhanced-recovery pathways. A distinction was made between studies demonstrating an association between a potentially modifiable risk factor and outcome and studies providing evidence that modification of that factor altered risk.

Methodological quality of non-randomised cohort and case-control studies was assessed using the Newcastle-Ottawa Scale (NOS). Prediction-model studies were additionally considered using principles from the Prediction model Risk Of Bias ASsessment Tool (PROBAST), with attention to participant selection, predictor definition, outcome assessment, model overfitting, validation, calibration and discrimination. Additional concerns included retrospective design, residual confounding, administrative coding, mixed hip and knee populations and possible cohort overlap.

Considerable clinical and methodological heterogeneity was present across populations, exposures, outcomes, follow-up and statistical methods; therefore, quantitative meta-analysis was not considered appropriate and findings were synthesised narratively. Greater emphasis was placed on adjusted analyses and rTHA-specific findings. Potentially overlapping cohorts were not interpreted as fully independent confirmation of the same association. Ethical approval was not required because this review synthesised previously published data and involved no recruitment or access to identifiable patient information.

Results

Study selection

The database search identified 226 records across PubMed, MEDLINE and Embase. After removal of 123 duplicates, 103 unique records remained for title and abstract screening. Eighty-six records were excluded because they did not meet the inclusion criteria or were not relevant to the review question. Seventeen reports were retrieved and assessed for eligibility; two were excluded because they were review articles rather than primary clinical studies. Fifteen primary studies were therefore included in the final systematic review (Figure 1).

Figure 1
Figure 1.PRISMA 2020 flow diagram of study selection.

Abbreviations: NOS, Newcastle-Ottawa Scale; PROBAST, Prediction model Risk Of Bias ASsessment Tool; rTHA, revision total hip arthroplasty; TJA, total joint arthroplasty.

Study characteristics

The 15 included studies were published between 2017 and 2026 and were predominantly observational, comprising retrospective institutional cohorts, administrative or registry database studies, case-control analyses and prediction-model studies. No randomised controlled trial was identified. Several studies exclusively examined rTHA, whereas others included combined revision hip and knee populations. Both aseptic and septic revisions were represented. The main domains were anaemia and blood management; nutritional status; opioid exposure; psychological comorbidity; renal and hepatic dysfunction; obesity and overall comorbidity burden; pulmonary risk; and enhanced-recovery pathways. No eligible primary study directly evaluated a structured preoperative exercise or physiotherapy intervention specifically in rTHA. Study characteristics are summarised in Table 1.

Table 1.Characteristics and principal findings of included studies
Study Design / data source Population Preoperative factor or strategy Principal outcomes Main findings
Sutton et al., 2026 - anaemia thresholds Retrospective single-centre cohort with simulated thresholds; 2019-2024 1,118 rTHAs Haematocrit / haemoglobin Transfusion, readmission, complications, discharge destination Lower haematocrit groups had greater adverse-event rates. Hb thresholds associated with lower event likelihood ranged 11.8-12.7 g/dL; strongest discrimination was for transfusion.
Sutton et al., 2026 - haemoglobin thresholds Retrospective single-centre prediction study; 2019-2024 rTHA and rTKA Preoperative haemoglobin Perioperative transfusion and composite adverse events rTHA transfusion thresholds were 13.0 g/dL for men and 12.0 g/dL for women. Prediction was stronger for transfusion than broader adverse events; possible cohort overlap with preceding study.
Gu et al., 2021 Retrospective ACS-NSQIP cohort; 2006-2017 8,932 rTHA; 13,313 rTKA Anaemia severity 30-day complications and mortality Moderate-to-severe anaemia independently associated with markedly increased complications after rTHA (OR 5.437).
Chen et al., 2021 Retrospective ACS-NSQIP cohort; 2007-2014 8,898 aseptic rTHAs Renal function / eGFR Complications, transfusion, cardiac events, LOS eGFR <30 mL/min independently associated with overall complications, cardiac complications, transfusion and prolonged LOS.
Rullan et al., 2023 Retrospective ACS-NSQIP cohort; 2011-2019 23,501 rTHAs Age, comorbidity, septic status, functional status, BMI 30-day mortality Overall mortality 0.69%; mortality increased with age and comorbidity burden and was higher following septic than aseptic revision.
Klemt et al., 2023 Retrospective prediction-model study 2,588 consecutive rTHAs; 408 re-revisions Multiple preoperative patient and surgical predictors Re-revision ASA score, BMI >35 kg/m2 and revision indication were major predictors. Four machine-learning models achieved AUC >0.80.
Guntin et al., 2023 Retrospective cohort 199 two-stage revisions for PJI; 69 hips Hypoalbuminaemia Treatment failure, mortality, LOS Hypoalbuminaemia before stage 2 predicted mortality (OR 5.40) and greater LOS but not septic treatment failure.
Traverso et al., 2023 Retrospective single-centre case-control study One-stage revision hip/knee arthroplasty for PJI Albumin, TLC and other nutritional markers Septic failure Albumin <3.5 g/dL independently associated with failure (OR 5.64); composite malnutrition measure was not significant.
Wilson et al., 2022 - opioids Retrospective MarketScan cohort rTHA Preoperative opioid exposure and six-month opioid-free interval Infection, wound complications, sepsis, revision, utilisation Continuous opioid use increased multiple complications. A six-month opioid-free interval was associated with risk comparable with opioid-naive patients for reported comparisons.
Wilson et al., 2020 - depression Retrospective MarketScan cohort 10,017 rTHAs; 13,973 rTKAs Preoperative depression LOS, discharge, readmission, ED attendance, infection, re-revision, costs Depression independently associated with increased utilisation, infection/PJI, sepsis and subsequent revision after rTHA.
Traven et al., 2017 Retrospective case-control study 126 revision hip/knee arthroplasties Vitamin D status 30-day readmission, 90-day complications, PJI Low vitamin D associated with increased 90-day complications but not 30-day readmission.
Kinnard et al., 2024 Retrospective ACS-NSQIP cohort; 2006-2019 7,102 rTHAs; 8,378 rTKAs Liver disease; MELD-Na >10 Major/wound/septic complications, transfusion, LOS, readmission Liver disease independently associated with increased postoperative morbidity and healthcare utilisation.
Huang et al., 2024 Retrospective Nationwide Inpatient Sample analysis; 2010-2019 112,735 revision THA admissions Medical comorbidity profile Pulmonary complications PPC incidence 2.62%; pulmonary vascular disease, electrolyte disorders, weight loss, CHF, chronic pulmonary disease and renal failure were among associated factors.
Lindberg-Larsen et al., 2022 Multicentre observational cohort / Danish Hip Arthroplasty Register; 2010-2018 1,345 elective aseptic major-component rTHAs Fast-track pathway and patient risk factors LOS and 90-day readmission Median LOS declined from 6 to 2 days; readmission remained >20%. Anaemia, obesity, psychiatric disease, impaired mobility and comorbidity identified higher-risk patients.
Rao et al., 2021 Retrospective tertiary-centre cohort; 2016-2018 251 lower-extremity revision TJAs Haemoglobin, infection, procedural complexity, TXA Allogeneic blood transfusion Preoperative anaemia, infection and procedural complexity increased transfusion risk; TXA was associated with reduced transfusion (OR 0.47).

Abbreviations: ACS-NSQIP, American College of Surgeons National Surgical Quality Improvement Program; ASA, American Society of Anesthesiologists; AUC, area under the curve; BMI, body mass index; CHF, congestive heart failure; ED, emergency department; eGFR, estimated glomerular filtration rate; Hb, haemoglobin; LOS, length of stay; MELD-Na, Model for End-Stage Liver Disease-Sodium; PJI, periprosthetic joint infection; PPC, postoperative pulmonary complication; rTHA, revision total hip arthroplasty; rTKA, revision total knee arthroplasty; TJA, total joint arthroplasty; TLC, total lymphocyte count; TXA, tranexamic acid.

Anaemia and blood optimisation

Anaemia was the most frequently investigated potentially modifiable factor. Gu et al. evaluated 8,932 rTHAs and 13,313 revision total knee arthroplasties and found a graded relationship between anaemia severity and adverse outcomes; after multivariable adjustment, moderate-to-severe anaemia was associated with more than fivefold greater odds of any 30-day complication after rTHA (OR 5.437, 95% CI 4.604-6.421; P<0.001).9 Two studies by Sutton et al. examined clinically useful haemoglobin or haematocrit thresholds.10,11 In 1,118 rTHAs, thresholds associated with lower likelihood of individual adverse outcomes ranged from approximately 11.8 to 12.7 g/dL, with strongest discrimination for intraoperative transfusion (AUC 0.770).10 In a related rTHA/rTKA cohort, thresholds associated with transfusion after rTHA were 13.0 g/dL in men and 12.0 g/dL in women; predictive performance was weaker for broader adverse events.11 These studies were derived from the same institution and overlapping 2019-2024 periods and were considered potentially overlapping rather than independent cohorts.

Rao et al. similarly identified preoperative haemoglobin as an independent predictor of perioperative allogeneic transfusion in 251 lower-extremity revision arthroplasties; infection and procedural complexity also increased transfusion risk, whereas tranexamic acid use was associated with lower odds (OR 0.47, 95% CI 0.23-0.98).12 In 1,345 elective aseptic rTHAs undertaken within six Danish fast-track centres, preoperative haemoglobin <=13 g/dL was also associated with prolonged admission and readmission.13

Nutritional status

Three studies examined nutritional markers. Guntin et al. evaluated 199 patients undergoing two-stage revision for PJI, including 69 hip revisions. Hypoalbuminaemia was not associated with overall or septic treatment failure but, when present before second-stage reimplantation, independently predicted mortality (OR 5.40, 95% CI 1.19-24.54; P=0.029) and increased length of stay.14 Traverso et al. found albumin <3.5 g/dL to be an independent predictor of failure after one-stage septic hip or knee revision (OR 5.64, 95% CI 1.26-25.18; P=0.023), while total lymphocyte count, haemoglobin, glucose and a composite malnutrition definition were not significant; model discrimination was modest (AUC 0.67).15 Traven et al., in 126 revision hip and knee arthroplasties, found low vitamin D associated with increased 90-day complications but not 30-day readmission.16

Opioid exposure and psychological comorbidity

Wilson et al. reported that 62.5% of rTHA patients had received an opioid prescription during the preceding year. Continuous preoperative use was associated with infection (OR 1.29), wound complications (OR 1.36), sepsis (OR 1.90), subsequent revision (OR 1.54) and greater healthcare utilisation. Patients with previous chronic exposure who subsequently experienced a six-month opioid-free interval had risks not significantly different from opioid-naive patients for reported comparisons.17

In a separate MarketScan study of 10,017 rTHAs, preoperative depression was independently associated with prolonged length of stay, non-home discharge, 90-day readmission, emergency department attendance, PJI, sepsis and subsequent revision.18 Pharmacologically treated psychiatric disease was also associated with prolonged admission and readmission in the Danish fast-track cohort.13

Renal, hepatic, pulmonary and general medical risk

Chen et al. assessed 8,898 aseptic rTHAs and found that eGFR <30 mL/min independently increased the odds of any complication (OR 1.447), cardiac complications (OR 3.344), transfusion (OR 1.623) and prolonged hospitalisation (OR 2.392).19 Kinnard et al. evaluated 7,102 aseptic rTHAs and 8,378 revision TKAs; liver disease was independently associated with major, wound and septic complications, transfusion, prolonged admission and readmission.20

Huang et al. analysed 112,735 revision THA admissions from the Nationwide Inpatient Sample and reported postoperative pulmonary complications in 2.62%, including pneumonia in 1.24%, acute respiratory failure in 1.31% and pulmonary embolism in 0.41%. Pulmonary circulatory disorders, fluid and electrolyte disorders, weight loss, heart failure, chronic pulmonary disease and renal failure were among associated factors.21 Rullan et al. evaluated 23,501 rTHAs and reported 30-day mortality of 0.69%; mortality increased substantially with age and comorbidity burden and was higher after septic than aseptic revision (1.03% vs 0.65%).22

Obesity, prediction and enhanced-recovery pathways

Klemt et al. developed four machine-learning models in 2,588 rTHAs, of which 408 (15.7%) underwent re-revision. ASA classification, BMI >35 kg/m2 and revision indication were among the strongest predictors; all models achieved AUC values >0.80.23 In the fast-track cohort, BMI >=35 kg/m2, use of a walking aid, advanced age, cardiac disease and previous revision were associated with prolonged length of stay, while pulmonary disease, psychiatric disease, low haemoglobin and walking-aid use were among factors associated with readmission.13 Median length of stay fell from 6 days in 2010 to 2 days in 2018, but 90-day readmission remained approximately 20% overall.13

Risk of bias and overall pattern of evidence

Risk-of-bias assessment is summarised in Table 2. Overall methodological quality was moderate, but no study was free from important limitations. Large database studies benefited from sample size and multivariable adjustment but remained susceptible to coding error, residual confounding and limited clinical granularity. Smaller single-centre studies were more vulnerable to selection bias and limited generalisability. Threshold and machine-learning studies carried additional concerns regarding overfitting, model validation and generalisability, and the two Sutton anaemia studies appeared to contain overlapping institutional cohorts.10,11

Table 2.Risk-of-bias assessment of included studies
Study Study type Appraisal approach Main concerns Overall judgement
Sutton et al., 2026 - anaemia thresholds Retrospective single-centre threshold/prediction study PROBAST-informed Retrospective, single-centre; threshold derivation; limited external validation; possible overfitting High
Sutton et al., 2026 - haemoglobin thresholds Retrospective single-centre threshold/prediction study PROBAST-informed Mixed hip/knee cohort; threshold derivation; limited external validation; possible overlap with related study High
Gu et al., 2021 Retrospective database cohort NOS Large adjusted cohort, but retrospective NSQIP data and short-term outcomes Moderate
Chen et al., 2021 Retrospective database cohort NOS Large sample and adjustment; residual confounding; NSQIP coding limitations Moderate
Rullan et al., 2023 Retrospective database cohort NOS Large sample; observational design, limited granularity and causal inference Moderate
Klemt et al., 2023 Retrospective machine-learning prediction study PROBAST Potential overfitting; predictor-outcome modelling; limited external validation High
Guntin et al., 2023 Retrospective cohort NOS Small mixed hip/knee septic cohort; selection bias; albumin may reflect systemic illness Moderate-high
Traverso et al., 2023 Retrospective case-control study NOS Small single-centre septic cohort; mixed hip/knee revisions; modest discrimination Moderate-high
Wilson et al., 2022 - opioids Retrospective claims database cohort NOS Claims-based exposure/outcome coding; residual confounding; prescriptions may not equal consumption Moderate
Wilson et al., 2020 - depression Retrospective claims database cohort NOS Claims-coded diagnosis; residual confounding; causality cannot be established Moderate
Traven et al., 2017 Retrospective case-control study NOS Small mixed hip/knee cohort; limited adjustment; risk of type I/II error High
Kinnard et al., 2024 Retrospective database cohort NOS Large adjusted cohort; indirect liver-disease definition; residual confounding Moderate
Huang et al., 2024 Retrospective Nationwide Inpatient Sample study NOS Very large sample, but coding-based inpatient dataset with limited clinical detail Moderate
Lindberg-Larsen et al., 2022 Multicentre observational cohort NOS Strong real-world multicentre design but non-randomised with centre-level confounding Moderate
Rao et al., 2021 Retrospective institutional cohort NOS Small mixed lower-extremity revision cohort; single centre; limited external validity Moderate-high

Across the evidence base, lower haemoglobin, hypoalbuminaemia, chronic opioid exposure, depression, severe renal impairment, liver disease, obesity and greater medical comorbidity were associated with poorer outcomes. However, most studies assessed prognostic associations rather than active optimisation. Evidence directly evaluating reversal of preoperative risk was limited; the opioid study provided observational evidence that an opioid-free interval was associated with attenuation of excess risk, and the fast-track study evaluated outcomes within an established enhanced-recovery system.13,17 No eligible study directly tested whether correction of anaemia, hypoalbuminaemia, vitamin D deficiency, obesity, depression or chronic medical disease improved rTHA outcomes, and no revision-specific study evaluated structured exercise-based prehabilitation or physiotherapy.

Discussion

Principal findings

This systematic review demonstrates that several preoperative patient factors are consistently associated with adverse outcomes following rTHA, but the strength and clinical meaning of these associations vary. Anaemia was the most consistently investigated potentially modifiable factor and was repeatedly associated with transfusion, complications, prolonged hospitalisation and readmission.9–13 Nutritional abnormalities, particularly hypoalbuminaemia, were associated with mortality, prolonged stay and failure in septic revision populations.14–16 Chronic opioid exposure and depression were associated with complications and increased healthcare utilisation, while renal dysfunction, liver disease, obesity, poor functional status and broader comorbidity burden further identified high-risk groups.13,17–23

The central limitation of the evidence is the discrepancy between the language of optimisation and the nature of the studies. Most were prognostic rather than interventional: they identified factors associated with outcome but did not demonstrate that correction of those factors reduced postoperative risk. A biomarker may therefore represent multimorbidity, systemic inflammation, frailty or disease severity rather than an independently reversible cause of complications. The present findings support systematic identification of high-risk patients and plausible targets for intervention, but they should not be interpreted as proof that normalisation of every abnormal preoperative variable will improve outcome.

Anaemia and patient blood management

Anaemia has the strongest and most consistent revision-specific evidence. Gu et al. demonstrated a graded association between anaemia severity and postoperative complications, while the Sutton studies proposed clinically meaningful haemoglobin and haematocrit thresholds and Rao et al. identified preoperative haemoglobin as an independent predictor of transfusion.9–12 Low haemoglobin also remained relevant within a dedicated fast-track pathway.13 These findings are biologically plausible because revision surgery may involve substantial blood loss, prolonged operating time, component removal and reconstruction.

The direction of these findings is consistent with the wider arthroplasty literature. Enhanced Recovery After Surgery recommendations for primary hip and knee replacement advocate identification and correction of preoperative anaemia, and meta-analytic evidence suggests that preoperative iron treatment in anaemic elective arthroplasty patients can reduce transfusion requirements and length of stay.24,25 In rTHA, however, current evidence does not establish that surgery should be delayed until a universal haemoglobin threshold is reached. The Sutton studies used simulated thresholds and overlapping institutional cohorts rather than prospective treatment assignment.10,11 Their values are therefore better regarded as risk-stratification signals than validated eligibility cut-offs. Prospective trials of iron replacement or comprehensive patient blood-management pathways specifically in rTHA are warranted.

Nutrition and metabolic optimisation

Hypoalbuminaemia was associated with mortality, prolonged hospitalisation and failure in septic revision cohorts, while low vitamin D was associated with 90-day complications in a smaller mixed hip and knee cohort.14–16 These findings are broadly consistent with primary arthroplasty evidence linking hypoalbuminaemia with infection, sepsis, transfusion, reoperation and mortality.26 Nevertheless, albumin is influenced by inflammation, infection, hepatic function, hydration and chronic disease as well as nutritional intake. In patients with PJI it may therefore be a marker of systemic illness rather than an isolated protein deficiency. Nutritional screening appears reasonable, but evidence that increasing serum albumin itself improves revision outcomes is lacking. Future studies should consider recent weight loss, dietary intake, sarcopenia and targeted nutritional interventions rather than relying on a single biochemical marker.

Opioid exposure and psychological health

Preoperative opioid exposure is one of the more clinically actionable findings. Continuous use before rTHA was associated with infection, wound complications, sepsis, re-revision and greater healthcare utilisation, while patients who achieved a six-month opioid-free interval had risk more comparable with opioid-naive patients.17 The direction of effect accords with systematic reviews in primary total joint arthroplasty showing worse patient-reported outcomes and higher complication or revision risk among preoperative opioid users.27,28 Although the observational design prevents attribution of causality, preoperative review of opioid dose, duration and indication, with planned rationalisation where clinically appropriate, is a reasonable component of multidisciplinary optimisation.

Depression was similarly associated with prolonged admission, non-home discharge, readmission, emergency attendance, PJI, sepsis and further revision after rTHA.18 Broader arthroplasty literature also associates depression with persistent pain, poorer satisfaction, adverse events and increased healthcare expenditure.29 Depression should not be considered a contraindication to revision surgery, but psychological assessment may identify patients who would benefit from optimisation of treatment, mental-health support, pain-management input and clearer expectation setting. Whether psychological intervention before rTHA modifies complications remains unknown.

Comorbidity, functional status and enhanced recovery

Severe renal dysfunction, liver disease, cardiopulmonary disease, obesity, impaired mobility and greater comorbidity burden were associated with adverse outcomes across several studies.13,19–23 These variables illustrate an important distinction between modifiable disease, modifiable consequences of disease and non-modifiable risk. Age, revision indication and number of previous revisions cannot be optimised; severe established renal or hepatic disease may also be only partly modifiable. Their value lies in directing anaesthetic or perioperative medicine input, medication review, correction of fluid or electrolyte abnormalities, discharge planning, informed consent and enhanced postoperative monitoring. Narrative work focused specifically on revision hip arthroplasty similarly highlights anaemia, obesity, malnutrition, diabetes, smoking, coagulopathy and infection-related factors as relevant considerations.30

The multicentre fast-track cohort provides evidence that enhanced-recovery principles are feasible in revision surgery: median length of stay decreased substantially, although 90-day readmission remained high and patient-specific risk factors continued to influence outcome.13 This suggests that revision pathways cannot simply replicate those developed for uncomplicated primary arthroplasty. A revision-specific pathway may need to integrate anaemia and nutritional assessment, medication and opioid review, optimisation of major organ disease, psychological screening, functional assessment, anaesthetic review and individualised discharge planning. Current ERAS recommendations for primary arthroplasty support several of these principles, including anaemia correction, education, smoking and alcohol modification, opioid-sparing analgesia and early mobilisation.24

The evidence gap for physiotherapy and lifestyle intervention

One of the most important findings was the absence of revision-specific intervention evidence for structured physiotherapy or exercise-based prehabilitation. This contrasts with primary THA, where recent systematic evidence has evaluated resistance training, home exercise, multidomain exercise, tele-prehabilitation and education.31,32 The relevance of these findings to revision surgery remains uncertain. Revision patients may have greater muscle deconditioning, chronic pain and functional decline and could potentially gain more from prehabilitation, yet infection, instability, periprosthetic fracture or severe implant failure may reduce the time available or make exercise unsafe. Elective aseptic rTHA therefore appears the most suitable initial population for prospective feasibility trials.

A similar gap exists for lifestyle interventions such as smoking cessation and alcohol reduction. These are commonly incorporated into primary arthroplasty optimisation pathways and are supported within ERAS guidance,24 but the present review did not identify primary revision-specific studies demonstrating improved rTHA outcomes following these interventions. Established general health recommendations remain reasonable, but the magnitude of any revision-specific benefit should not be overstated.

Clinical implications and future research

The findings suggest a practical three-part framework. First, potentially correctable abnormalities with plausible direct perioperative effects, particularly anaemia and selected nutritional deficiencies, should be identified sufficiently early to allow investigation and treatment.9–12,14–16 Second, modifiable exposures or conditions such as chronic opioid use, poorly controlled psychological illness, obesity and inadequately managed medical comorbidity may merit targeted intervention, although optimal strategies and timing are uncertain.17–21 Third, non-modifiable or incompletely modifiable risk markers such as age, previous revision burden, revision indication and severe established organ disease remain valuable for counselling and planning.13,19–23 This is preferable to rigid numerical eligibility criteria because rTHA ranges from limited elective component exchange to major reconstruction for infection, bone loss or periprosthetic fracture, where urgency and opportunity for optimisation differ considerably.33

Future research should shift from retrospective risk-factor identification towards prospective intervention testing. Priority areas include structured anaemia management, comprehensive nutritional assessment, opioid-reduction protocols, psychological support and multimodal optimisation bundles. Physical prehabilitation is a particularly clear unanswered question and could initially be studied in elective aseptic revision patients with sufficient lead time before surgery. Multicentre prospective designs should stratify by indication and procedural complexity and report outcomes including complications, transfusion, length of stay, readmission, discharge destination, functional recovery and cost-effectiveness.

Limitations

This review has several limitations. The evidence base was overwhelmingly retrospective and observational, limiting causal inference and leaving substantial potential for residual confounding. Several studies relied on administrative datasets with limited clinical granularity and dependence on coding accuracy.9,17–22 Mixed hip and knee populations were included where rTHA formed a defined component, and pooled findings cannot always be assumed to apply identically to revision hip surgery. Septic and aseptic revisions also represent clinically distinct populations; infection may itself drive anaemia, hypoalbuminaemia and systemic illness. Heterogeneity in exposures, outcomes and follow-up precluded meaningful meta-analysis. Potential cohort overlap existed between the two Sutton anaemia studies.10,11 Finally, restriction to English-language publications may have excluded relevant data. The absence of physiotherapy, exercise and lifestyle intervention studies should therefore be interpreted as a gap in revision-specific evidence rather than evidence that these approaches are ineffective.

Conclusion

Revision total hip arthroplasty is performed in a clinically complex and heterogeneous population in whom preoperative health status is strongly associated with postoperative outcome. Anaemia has the most consistent revision-specific evidence and represents a particularly plausible target for investigation and treatment. Hypoalbuminaemia, chronic opioid exposure, depression, obesity and significant renal, hepatic and cardiopulmonary disease also identify higher-risk patients and may inform intervention or perioperative planning.

However, the existing literature largely identifies who is at risk rather than demonstrating how that risk should be reduced. Most studies were retrospective and observational, and direct interventional evidence was limited. No eligible revision-specific study directly evaluated structured physiotherapy or exercise-based prehabilitation. Preoperative management of rTHA should therefore combine multidisciplinary identification and treatment of reversible abnormalities with optimisation of major medical and psychological comorbidity and risk-informed perioperative planning. Prospective multicentre interventional studies are required to determine which individual or multimodal strategies produce meaningful improvements in revision THA outcomes.


Acknowledgements

N/A

Author Contributions

Author contributions: Bekim Arifaj, Mohamed Habad, and Mubaraq Hamzat contributed equally to this work and should be considered co-first authors. Bekim Arifaj, Mohamed Habad, and Mubaraq Hamzat were responsible for conceptualization, methodology, literature searching, study screening, data extraction, risk-of-bias assessment, formal analysis, and drafting the original manuscript. Marek Webb and Eid-Christian Oweis contributed to study design, interpretation of findings and critical revision of the manuscript. All authors reviewed and approved the final manuscript and agree to be accountable for the integrity of the work.

Bekim Arifaj, Mohamed Habad, and Mubaraq Hamzat contributed equally to this work and share first authorship.

Conflicts of Interest

Conflicts of interest: none

Funding

Funding: none

Conference Presentation

Conference presentation: none

Accepted: October 31, 2026 EDT

References

1.
Shichman I, Askew N, Habibi A, Nherera L, Macaulay W, Seyler T, et al. Projections and epidemiology of revision hip and knee arthroplasty in the United States to 2040-2060. Arthroplast Today. 2023;21:101152. doi:10.1016/​j.artd.2023.101152
Google Scholar
2.
Schwartz AM, Farley KX, Guild GN, Bradbury TL Jr. Projections and epidemiology of revision hip and knee arthroplasty in the United States to 2030. J Arthroplasty. 2020;35(6 Suppl):S79-S85. doi:10.1016/​j.arth.2020.02.030
Google Scholar
3.
Bains SS, Dubin JA, Salib CG, Monarrez R, Remily E, Hameed D, et al. The epidemiology of the revision total hip arthroplasty in the United States from 2016 to 2022. Arthroplast Today. 2024;30:101517. doi:10.1016/​j.artd.2024.101517
Google Scholar
4.
Postler AE, Beyer F, Wegner T, Lutzner J, Hartmann A, Ojodu I, et al. Patient-reported outcomes after revision surgery compared to primary total hip arthroplasty. Hip Int. 2017;27(2):180-186. doi:10.5301/​hipint.5000436
Google Scholar
5.
Zhang S, Chen JY, Pang HN, Lo NN, Yeo SJ, Liow MHL. Revision total hip arthroplasty is associated with poorer clinically meaningful improvements and patient satisfaction compared to primary total hip arthroplasty. J Orthop. 2021;28:96-100. doi:10.1016/​j.jor.2021.11.008
Google Scholar
6.
Laughlin MS, Vidal EA, Drtil AA, Goytia RN, Mathews V, Patel AR. Mortality after revision total hip arthroplasty. J Arthroplasty. 2021;36(7):2353-2358. doi:10.1016/​j.arth.2021.01.022
Google Scholar
7.
Vanhegan IS, Malik AK, Jayakumar P, Ul Islam S, Haddad FS. A financial analysis of revision hip arthroplasty: the economic burden in relation to the national tariff. J Bone Joint Surg Br. 2012;94(5):619-623. doi:10.1302/​0301-620X.94B5.27073
Google Scholar
8.
MacMahon A, Rao SS, Chaudhry YP, Hasan SA, Epstein JA, Hegde V, et al. Preoperative patient optimization in total joint arthroplasty-the paradigm shift from preoperative clearance: a narrative review. HSS J. 2022;18(3):418-427. doi:10.1177/​15563316211030923
Google Scholar
9.
Gu A, Chen AZ, Selemon NA, Tornberg H, Wei C, Fassihi SC, et al. Preoperative anemia independently predicts significantly increased odds of short-term complications following aseptic revision hip and knee arthroplasty. J Arthroplasty. 2021;36(5):1719-1728. doi:10.1016/​j.arth.2020.10.061
Google Scholar
10.
Sutton R, Leipman JH, Linton A, Sherman MB, Martinazzi BJ, Fellheimer HS, et al. Defining preoperative anemia thresholds for revision total hip arthroplasty. J Arthroplasty. 2026;41(7):2130-2137. doi:10.1016/​j.arth.2025.10.043
Google Scholar
11.
Sutton R, Sherman MB, Leipman JH, Linton A, Martinazzi BJ, Fillingham YA. Defining preoperative hemoglobin thresholds can help avoid transfusion or adverse events for revision total joint arthroplasty. J Arthroplasty. 2026;41(8):2467-2472.e1. doi:10.1016/​j.arth.2025.10.055
Google Scholar
12.
Rao SS, Chaudhry YP, Hasan SA, Puvanesarajah V, Amin RM, Oni JK, et al. Factors associated with perioperative transfusion in lower extremity revision arthroplasty under a restrictive blood management protocol. J Am Acad Orthop Surg. 2021;29(8):e404-e409. doi:10.5435/​JAAOS-D-20-00185
Google Scholar
13.
Lindberg-Larsen M, Petersen PB, Corap Y, Gromov K, Jorgensen CC, Kehlet H, et al. Fast-track revision hip arthroplasty: a multicenter cohort study on 1,345 elective aseptic major component revision hip arthroplasties. Acta Orthop. 2022;93:341-347. doi:10.2340/​17453674.2022.2196
Google Scholar
14.
Guntin J, Serino J, Rossi D, Boniello A, Gusho CA, Della Valle CJ. Hypoalbuminemia increases mortality after two-stage revision total joint arthroplasty. Arch Bone Jt Surg. 2023;11(3):173-179. doi:10.22038/​ABJS.2022.65148.3123
Google Scholar
15.
Traverso G, Nunez JH, Gehrke T, Citak M. Hypoalbuminemia increases the risk of failure following one-stage septic revision for periprosthetic joint infection. Arch Orthop Trauma Surg. 2023;143(9):5641-5648. doi:10.1007/​s00402-023-04885-z
Google Scholar
16.
Traven SA, Chiaramonti AM, Barfield WR, Kirkland PA, Demos HA, Schutte HD, et al. Fewer complications following revision hip and knee arthroplasty in patients with normal vitamin D levels. J Arthroplasty. 2017;32(9 Suppl):S193-S196. doi:10.1016/​j.arth.2017.02.038
Google Scholar
17.
Wilson JM, Farley KX, Erens GA, Bradbury TL, Guild GN 3rd. Preoperative opioid use is a risk factor for complication following revision total hip arthroplasty. Hip Int. 2022;32(3):363-370. doi:10.1177/​1120700020947400
Google Scholar
18.
Wilson JM, Farley KX, Erens GA, Bradbury TL, Guild GN. Preoperative depression is associated with increased risk following revision total joint arthroplasty. J Arthroplasty. 2020;35(4):1048-1053. doi:10.1016/​j.arth.2019.11.025
Google Scholar
19.
Chen AZ, Gu A, Selemon NA, Cohen JS, Wei C, Tornberg H, et al. Preoperative estimated glomerular filtration rate is a marker for postoperative complications following aseptic revision total hip arthroplasty. Eur J Orthop Surg Traumatol. 2021;31(1):175-182. doi:10.1007/​s00590-020-02761-9
Google Scholar
20.
Kinnard MJ, Cohen JS, Quan T, Foran JRH, Sheth NP. Liver disease increases the risk of postoperative complications in patients undergoing aseptic revision total hip and knee arthroplasty. Arthroplast Today. 2024;29:101516. doi:10.1016/​j.artd.2024.101516
Google Scholar
21.
Huang L, Huang X, Lin J, Yang Q, Zhu H. Incidence and risk factors of postoperative pulmonary complications following total hip arthroplasty revision: a retrospective Nationwide Inpatient Sample database study. J Orthop Surg Res. 2024;19(1):353. doi:10.1186/​s13018-024-04836-3
Google Scholar
22.
Rullan PJ, Orr MN, Emara AK, Klika AK, Molloy RM, Piuzzi NS. Understanding the 30-day mortality burden after revision total hip arthroplasty. Hip Int. 2023;33(4):727-735. doi:10.1177/​11207000221094543
Google Scholar
23.
Klemt C, Cohen-Levy WB, Robinson MG, Burns JC, Alpaugh K, Yeo I, et al. Can machine learning models predict failure of revision total hip arthroplasty? Arch Orthop Trauma Surg. 2023;143(6):2805-2812. doi:10.1007/​s00402-022-04453-x
Google Scholar
24.
Wainwright TW, Gill M, McDonald DA, Middleton RG, Reed M, Sahota O, et al. Consensus statement for perioperative care in total hip replacement and total knee replacement surgery: Enhanced Recovery After Surgery (ERAS) Society recommendations. Acta Orthop. 2020;91(1):3-19. doi:10.1080/​17453674.2019.1683790
Google Scholar
25.
Scrimshire AB, Booth A, Fairhurst C, Kotze A, Reed M, McDaid C. Preoperative iron treatment in anaemic patients undergoing elective total hip or knee arthroplasty: a systematic review and meta-analysis. BMJ Open. 2020;10(10):e036592. doi:10.1136/​bmjopen-2019-036592
Google Scholar
26.
Yue C, Li Y, Yang L, Li F, Wu X, Ma M, et al. Associations between preoperative hypoalbuminemia and clinical outcomes following total hip or knee arthroplasty: a systematic review and meta-analysis. EFORT Open Rev. 2026;11(4):268-276. doi:10.1530/​EOR-2025-0170
Google Scholar
27.
Goplen CM, Verbeek W, Kang SH, Jones CA, Voaklander DC, Churchill TA, et al. Preoperative opioid use is associated with worse patient outcomes after total joint arthroplasty: a systematic review and meta-analysis. BMC Musculoskelet Disord. 2019;20(1):234. doi:10.1186/​s12891-019-2619-8
Google Scholar
28.
Malahias MA, Loucas R, Loucas M, Denti M, Sculco PK, Greenberg A. Preoperative opioid use is associated with higher revision rates in total joint arthroplasty: a systematic review. J Arthroplasty. 2021;36(11):3814-3821. doi:10.1016/​j.arth.2021.06.017
Google Scholar
29.
Vajapey SP, McKeon JF, Krueger CA, Spitzer AI. Outcomes of total joint arthroplasty in patients with depression: a systematic review. J Clin Orthop Trauma. 2021;18:187-198. doi:10.1016/​j.jcot.2021.04.028
Google Scholar
30.
Jaenisch M, Wirtz DC. Patient optimization before hip revision arthroplasty: how to handle comorbidities. Orthopadie (Heidelb). 2022;51(8):619-630. doi:10.1007/​s00132-022-04273-2
Google Scholar
31.
van der Vorst MAT, Dijkman R, Hannink G, van Hove RP, Olde Rikkert MGM, Peeters G. Effectiveness of prehabilitation modalities before total hip arthroplasty: a systematic review and network meta-analysis. Ann Phys Rehabil Med. 2026;69(4):102114. doi:10.1016/​j.rehab.2026.102114
Google Scholar
32.
Keogh JAJ, Keng I, Dhillon DS, Bourgeault-Gagnon Y, Simunovic N, Ayeni OR. The effects of structured prehabilitation on postoperative outcomes following total hip and total knee arthroplasty: an overview of systematic reviews and meta-analyses of randomized controlled trials. J Orthop Sports Phys Ther. 2025;55(5):344-365. doi:10.2519/​jospt.2025.13075
Google Scholar
33.
Morgan S, Bourget-Murray J, Garceau S, Grammatopoulos G. Revision total hip arthroplasty for periprosthetic fracture: epidemiology, outcomes, and factors associated with success. Ann Jt. 2023;8:30. doi:10.21037/​aoj-23-16
Google Scholar

Supplementary Appendix 1. Complete database search strategies

PubMed

((“Arthroplasty, Replacement, Hip”[Mesh] OR “hip arthroplasty”[Title/Abstract] OR “hip replacement”[Title/Abstract] OR THA[Title/Abstract]) AND (revision[Title/Abstract] OR revised[Title/Abstract] OR “revision arthroplasty”[Title/Abstract] OR “revision joint arthroplasty”[Title/Abstract] OR “revision total joint arthroplasty”[Title/Abstract]) AND (prehabilitat*[Title/Abstract] OR “preoperative rehabilitation”[Title/Abstract] OR “preoperative physiotherapy”[Title/Abstract] OR “preoperative physical therapy”[Title/Abstract] OR “preoperative exercise”[Title/Abstract] OR “preoperative optimisation”[Title/Abstract] OR “preoperative optimization”[Title/Abstract] OR “preoperative care”[Title/Abstract] OR “preoperative management”[Title/Abstract] OR “preoperative preparation”[Title/Abstract] OR “patient optimisation”[Title/Abstract] OR “patient optimization”[Title/Abstract] OR “lifestyle modification”[Title/Abstract] OR “risk factor modification”[Title/Abstract] OR “modifiable risk factor”[Title/Abstract]))

MEDLINE (Ovid)

(exp Arthroplasty, Replacement, Hip/ OR “hip arthroplasty”.ti,ab. OR “hip replacement”.ti,ab. OR THA.ti,ab.) AND (revision.ti,ab. OR revised.ti,ab. OR “revision arthroplasty”.ti,ab. OR “revision joint arthroplasty”.ti,ab. OR “revision total joint arthroplasty”.ti,ab.) AND (prehabilitat*.ti,ab. OR “preoperative rehabilitation”.ti,ab. OR “preoperative physiotherapy”.ti,ab. OR “preoperative physical therapy”.ti,ab. OR “preoperative exercise”.ti,ab. OR “preoperative optimisation”.ti,ab. OR “preoperative optimization”.ti,ab. OR “preoperative care”.ti,ab. OR “preoperative management”.ti,ab. OR “preoperative preparation”.ti,ab. OR “patient optimisation”.ti,ab. OR “patient optimization”.ti,ab. OR “lifestyle modification”.ti,ab. OR “risk factor modification”.ti,ab. OR “modifiable risk factor”.ti,ab.)

Embase (Ovid)

(exp hip arthroplasty/ OR exp hip prosthesis/ OR “hip arthroplasty”.ti,ab. OR “hip replacement”.ti,ab. OR THA.ti,ab.) AND (revision.ti,ab. OR revised.ti,ab. OR “revision arthroplasty”.ti,ab. OR “revision joint arthroplasty”.ti,ab. OR “revision total joint arthroplasty”.ti,ab.) AND (prehabilitat*.ti,ab. OR “preoperative rehabilitation”.ti,ab. OR “preoperative physiotherapy”.ti,ab. OR “preoperative physical therapy”.ti,ab. OR “preoperative exercise”.ti,ab. OR “preoperative optimisation”.ti,ab. OR “preoperative optimization”.ti,ab. OR “preoperative care”.ti,ab. OR “preoperative management”.ti,ab. OR “preoperative preparation”.ti,ab. OR “patient optimisation”.ti,ab. OR “patient optimization”.ti,ab. OR “lifestyle modification”.ti,ab. OR “risk factor modification”.ti,ab. OR “modifiable risk factor”.ti,ab.)